By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Meiji Seika Kaisha, Ltd. 

4-16-1, Hatchobori

Chuo-Ku  Tokyo  104-8002  Japan
Phone: 81-3-3272-6511 Fax: 81-3-3271-3528


SEARCH JOBS


Industry
Pharmaceutical






Company News
Celentyx Enters Into Agreement With Meiji Seika Kaisha, Ltd. To Discover New Development Paths For Meiji Drug Candidates Using Celentyx's Novel Clinical Indication Profiling(TM) 8/24/2009 11:54:55 AM
Amalyte and Meiji Seika Kaisha, Ltd. Enter Into a License, Development and Commercialization Agreement on AM3301 and a Novel Class of Anti-Inflammatory Compounds 6/8/2009 9:48:28 AM
ACADIA Pharmaceuticals, Inc. (ACAD) And Meiji Seika Kaisha, Ltd. Form Collaboration to Develop and Commercialize a New Class of Pro-Cognitive Schizophrenia Drugs 3/25/2009 10:18:42 AM
Symphogen A/S and Meiji Seika Kaisha, Ltd. Achieve Milestone in Discovery Collaboration for Recombinant Polyclonal Antibody, Sym006 12/4/2008 10:21:24 AM
Symphogen A/S And Meiji Seika Kaisha, Ltd. Enter Agreement For Recombinant Polyclonal Antibody Product 12/11/2006 12:50:10 PM
Cerexa, Inc. Expands Portfolio Of Novel Anti-Infective Therapies Through In-Licensing Agreement With Meiji Seika Kaisha, Ltd. 11/1/2006 12:24:23 PM
MediciNova, Inc. Announces The Acquisition Of Two Novel Antithrombotic Agents From Meiji Seika Kaisha, Ltd. 11/1/2006 11:18:37 AM
Meiji Seika Kaisha, Ltd. And Solvay Seiyaku Obtain Additional Approval For Fluvoxamine Maleate10/19/2005 5:13:22 PM
Nippon Organon KK Licenses Antidepressant To Meiji Seika Kaisha, Ltd.10/19/2005 5:11:19 PM
Meiji Seika Kaisha, Ltd. Subsidiary Receives Sales Approval For "MEIACT" In Spain10/19/2005 5:11:05 PM
12
//-->